1. Home
  2. MQ vs RAPP Comparison

MQ vs RAPP Comparison

Compare MQ & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marqeta Inc.

MQ

Marqeta Inc.

N/A

Current Price

$18.20

Market Cap

1.7B

Sector

Technology

ML Signal

N/A

Logo Rapport Therapeutics Inc.

RAPP

Rapport Therapeutics Inc.

N/A

Current Price

$26.23

Market Cap

1.4B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MQ
RAPP
Founded
2010
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
MQ
RAPP
Price
$18.20
$26.23
Analyst Decision
Hold
Strong Buy
Analyst Count
14
16
Target Price
$20.78
★ $64.21
AVG Volume (30 Days)
708.4K
★ 1.4M
Earning Date
11-03-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 24.34
EPS
★ N/A
N/A
Revenue
★ $624,884,000.00
N/A
Revenue This Year
$11.69
N/A
Revenue Next Year
$12.92
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 23.25
N/A
52 Week Low
$3.70
$22.06
52 Week High
$19.40
$52.93

Technical Indicators

Market Signals
Indicator
MQ
RAPP
Relative Strength Index (RSI) 51.10 44.08
Support Level $16.74 $22.51
Resistance Level $19.01 $31.49
Average True Range (ATR) 0.66 1.80
MACD -0.10 0.61
Stochastic Oscillator 62.44 62.39

Price Performance

Historical Comparison
MQ
RAPP

About MQ Marqeta Inc.

Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: